Volume 3.13 | Apr 7

Personalized Melanoma Vaccines Marshal Powerful Immune Response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors. The tailor-made vaccines, given to three patients with advanced melanoma, appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors. [Press release from Washington University in St. Louis discussing online prepublication in Science] Press Release|Abstract

The Future of Immune Checkpoint Therapy
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment. [Science] Abstract|Press Release

Visit our reviews page to see a complete list of reviews in the human immunology research field.

INDUSTRY NEWS

MD Anderson, Astellas Pharma Sign Option Agreement
The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc. have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia. The agreement includes up to $26 million as an option premium and for research and development funding. [The University of Texas MD Anderson Cancer Center] Press Release